| abstract |
FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to experimental pharmacology and ophthalmology, and can be used to treat ischemic neuropathy of the optic nerve. To do this, the pathology is modeled by daily intraperitoneal injection of non-selective NO-synthase inhibitor N-nitro-L-arginine-methyl ether at a dose of 12.5 mg/kg of rat weight for 28 days to laboratory male rats of the Wistar line. On the 26th day of the experiment, a single increase in the intraocular pressure to 110 mm Hg is additionally carried out for 5 minutes by applying mechanical pressure to the anterior chamber of the eye. Correction of the optic nerve pathology thus induced is carried out with a solution of 2-dimethylaminoethanol L-2-aminopentanedioate from the 29th day of the experiment for 28 days by daily intragastric administration at a dose of 25 mg/kg/day. n EFFECT: method provides expressed correction of ischemic neuropathy of the optic nerve, including by improving the retinal microcirculation and restoring the electrophysiological activity of the retina. n 1 cl, 1 tbl, 3 ex |